



4<sup>th</sup> February, 2025

To,  
**BSE Limited**  
P J Towers, Dalal Street,  
Fort, Mumbai- 400 001.

To,  
**National Stock Exchange of India Ltd**  
Exchange Plaza, Bandra Kurla Complex,  
Bandra(E), Mumbai- 400 051.

Scrip Code : 524518

Scrip Code : KREBSBIO

Dear Sir / Madam,

**Sub: Outcome of Board Meeting – Unaudited Financial Results for the 3<sup>rd</sup> quarter and nine months ended 31<sup>st</sup> December 2024.**

A. Pursuant to Regulation 30 and 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations 2015, we wish to inform that the Board of Directors of the Company at its meeting held today approved and taken on record the following:

1. Unaudited Financial Results of the Company for the 3<sup>rd</sup> quarter and nine months ended 31<sup>st</sup> December 2024.
2. Limited Review Report by the Auditors on the Unaudited Financial Results for the 3<sup>rd</sup> quarter and nine months ended 31<sup>st</sup> December 2024.

B. Based on the recommendation of the Nomination and Remuneration Committee, the Board has appointed Mr. Popatlal Mukanchand Kathariya (DIN: 00281395), Ms. Dipti Chinubhai Shah (DIN: 07995542), Mr. Satya Prakash Chigurupati (DIN : 00721318) and Mr. Sumanth Karlapudi (DIN: 09188185) as Additional Directors of the Company with effect from 4<sup>th</sup> February, 2025 and also appointed them as Independent Directors of the Company for a period of 5 years from 4<sup>th</sup> February, 2025 till 3<sup>rd</sup> February, 2030 subject to approval of shareholders.



Disclosure pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 of the Independent Directors appointed:

Name of Director	Mr. Popatlal Mukanchand Kathariya	Ms. Dipti Chinubhai Shah	Mr. Satya Prakash Chigurupati	Mr. Sumanth Karlapudi
<b>Reason for change</b>	Appointed as an Additional/Independent Director of the Company with effect from 4 <sup>th</sup> February, 2025.	Appointed as an Additional/Independent Director of the Company with effect from 4 <sup>th</sup> February, 2025.	Appointed as an Additional/Independent Director of the Company with effect from 4 <sup>th</sup> February, 2025.	Appointed as an Additional/Independent Director of the Company with effect from 4 <sup>th</sup> February, 2025.
<b>Date of appointment &amp; term of appointment:</b>	As an Independent Director for a period of 5 years from 4 <sup>th</sup> February, 2025 till 3 <sup>rd</sup> February, 2030 subject to approval of shareholders.	As an Independent Director for a period of 5 years from 4 <sup>th</sup> February, 2025 till 3 <sup>rd</sup> February, 2030 subject to approval of shareholders.	As an Independent Director for a period of 5 years from 4 <sup>th</sup> February, 2025 till 3 <sup>rd</sup> February, 2030 subject to approval of shareholders.	As an Independent Director for a period of 5 Years from 4 <sup>th</sup> February, 2025 till 3 <sup>rd</sup> February, 2030 subject to approval of shareholders.
<b>Brief profile</b>	Mr. P M Kathariya, aged 71 years is Graduate in Commerce and is a fellow member of the Institute of Chartered Accountant of India. Mr. P M Kathariya is practising as Chartered Accountants since 1978 and is having vast experience in the audit and taxation field.  Mr. P M Kathariya is not debarred from holding the office of Director by virtue of any SEBI	Ms. Dipti Shah, aged 51 years is by qualification is B.Com and LL.B and is also a Solicitor from England and Wales. She is practising as an Advocate at the High Court of Judicature at Mumbai and as Solicitor from England & Wales.  Ms. Dipti Shah is not debarred from holding the office of Director by virtue of any SEBI order or order by any other competent	Mr. Satya Prakash Chigurupati, aged 62 years is Graduate in Commerce and Law. He is a fellow member of the Institute of Chartered Accountant of India. He has worked in Cement Industry for 15 years as Chief of Finance and Accounts. Subsequently he started his own practice as Chartered Accountants and he is in practice for the past 20 years.	Mr. Sumanth Karlapudi, aged 37 years is Graduate in Commerce and Law. He is also a fellow member of the Institute of Chartered Accountant of India. Mr. Sumanth Karlapudi having vast experience in the filed of Finance, Taxation and Strategic Planning.  Mr. Sumanth Karlapudi is not debarred from holding the office of Director by virtue of any SEBI



	order or order by any other competent authority.	authority.	Mr. Satya Prakash Chigurupati is not debarred from holding the office of Director by virtue of any SEBI order or order by any other competent authority.	order or order by any other competent authority.
<b>Disclosure of relationships between directors</b>	Not related to any Director or Key Managerial Personnel of the Company.	Not related to any Director or Key Managerial Personnel of the Company.	Not related to any Director or Key Managerial Personnel of the Company.	Not related to any Director or Key Managerial Personnel of the Company.

- C. The Board has also reconstituted the following committees of the Board w.e.f. 4<sup>th</sup> February, 2025. The revised Board Committees will now comprise of the following Board Members:

<b>Audit Committee</b>	
Mr. P M Kathariya	Chairman of the Committee/Independent Director
Ms. Dipti Shah	Independent Director
Mr. Satya Prakash Chigurupati	Independent Director
Mr. Sumanth Karlapudi	Independent Director
Mr. Jitendra Shah	Managing Director & CEO

<b>Stakeholder Relationship Committee</b>	
Mr. Sumanth Karlapudi	Chairman of the Committee/Independent Director
Ms. Dipti Shah	Independent Director
Mr. Satya Prakash Chigurupati	Independent Director
Mr. P M Kathariya	Independent Director
Mr. Jitendra Shah	Managing Director & CEO

<b>Nomination and Remuneration Committee</b>	
Mr. Satya Prakash Chigurupati	Chairman of the Committee/Independent Director
Ms. Dipti Shah	Independent Director
Mr. P M Kathariya	Independent Director
Mr. Sumanth Karlapudi	Independent Director



D. In accordance to the SEBI (Listing Obligations and Disclosure Requirements) (Third Amendment) Regulations, 2024, the Integrated Filing (Financials) for the 3<sup>rd</sup> quarter and nine months ended 31<sup>st</sup> December 2024 is also enclosed herewith.

The Meeting of the Board of Directors commenced at 12:00 noon and concluded at 1:45 p.m.

The above is for your information and record.

Thanking you,  
Yours Faithfully,  
For **Krebs Biochemicals and Industries Limited**

**Rakesh R Kalbate**  
Company Secretary & Compliance Officer

Encl.: a/a.

KREBS BIOCHEMICALS & INDUSTRIES LIMITED  
CIN:L24110AP1991PLC103912

Registered Office: Kothapalli Village, Kasimkota Mandal, Anakapalli, Visakhapatnam, Andhra Pradesh - 531 031

STATEMENT OF UNAUDITED STANDALONE FINANCIAL RESULTS FOR THE QUARTER AND NINE MONTHS ENDED DECEMBER 31,2024


(Rs. In lacs)

Sr.No	Particulars	Quarter Ended			Nine Months Ended		Year Ended
		31.12.2024	30.09.2024	31.12.2023	31.12.2024	31.12.2023	31.03.2024
		(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Audited)
1	Revenue from Operations	1,146.72	1,285.52	1,297.72	3,721.14	3,844.86	5042.15
2	Other Income	25.12	8.62	2.94	37.09	24.11	45.13
3	<b>Total Income (1+2)</b>	<b>1,171.84</b>	<b>1,294.14</b>	<b>1,300.66</b>	<b>3,758.23</b>	<b>3,868.97</b>	<b>5,087.28</b>
4	<b>Expenses</b>	<b>118.51</b>	<b>103.42</b>	<b>103.09</b>	<b>259.22</b>	<b>362.51</b>	<b>543.17</b>
	a) Cost of Material Consumed	0.02	-	-	3.67	-	8.63
	b) Purchase of Stock in Trade	12.46	138.70	24.65	235.98	7.14	106.93
	c) Changes in Inventories of Finished goods, Work-In-Progress	450.42	439.12	444.47	1,314.44	1,259.74	1,647.41
	d) Employee Benefits Expenses	155.67	142.47	118.62	429.95	341.76	468.94
	e) Finance Costs	171.74	171.23	173.05	512.02	509.45	676.63
	f) Depreciation and Amortisation Expense	1,036.91	875.28	934.51	2,870.04	2,776.51	3,608.41
	g) Other Expenses	1,945.73	1,870.22	1,798.40	5,625.32	5,257.12	7,060.12
	<b>Total Expenses (4)</b>	<b>(773.89)</b>	<b>(576.08)</b>	<b>(497.74)</b>	<b>(1,867.09)</b>	<b>(1,388.15)</b>	<b>(1,972.84)</b>
5	Profit / (Loss) before exceptional items and tax (3-4)	-	-	-	-	-	-
6	Exceptional Items:	-	-	-	-	-	-
7	Profit / (Loss) before Tax (5 + 6)	(773.89)	(576.08)	(497.74)	(1,867.09)	(1,388.15)	(1,972.84)
8	<b>Tax Expense</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>
	a) Current Tax	-	-	-	-	-	-
	b) Deferred Tax	-	-	-	-	-	-
9	<b>Profit / (Loss) for the period from Continuing Operations (7+8)</b>	<b>(773.89)</b>	<b>(576.08)</b>	<b>(497.74)</b>	<b>(1,867.09)</b>	<b>(1,388.15)</b>	<b>(1,972.84)</b>
10	<b>Other Comprehensive Income</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>(2.60)</b>
	i) Items that will not be reclassified to profit or Loss	-	-	-	-	-	-
	ii) Income tax relating to items that will not be reclassified to profit or Loss	-	-	-	-	-	-
	iii) Items that will be reclassified to profit or Loss	-	-	-	-	-	-
	iv) Income tax relating to items that will be reclassified to profit or Loss	-	-	-	-	-	(2.60)
	<b>Other Comprehensive Income (Net of Tax)</b>	<b>(773.89)</b>	<b>(576.08)</b>	<b>(497.74)</b>	<b>(1,867.09)</b>	<b>(1,388.15)</b>	<b>(1,975.44)</b>
11	<b>Total Comprehensive Income for the period(9+10)</b>	<b>2,156.06</b>	<b>2,156.06</b>	<b>2,156.06</b>	<b>2,156.06</b>	<b>2,156.06</b>	<b>2,156.06</b>
12	Paid-up Equity Share Capital (Face Value Rs. 10/- each)	-	-	-	-	-	(15,182.81)
13	Other Equity excluding Revaluation Reserve	-	-	-	-	-	-
14	<b>Earning Per Share (of Rs.10/- each) (not Annualised)</b>	<b>(3.59)</b>	<b>(2.67)</b>	<b>(2.31)</b>	<b>(8.66)</b>	<b>(6.44)</b>	<b>(9.16)</b>
	a) Basic	(3.59)	(2.67)	(2.31)	(8.66)	(6.44)	(9.16)
	b) Diluted	-	-	-	-	-	(11,921.67)
15	<b>Net Worth (including Retained Earnings)</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>(11,921.67)</b>

**Notes:**

- The above unaudited standalone financial results as reviewed by the Audit Committee, were approved and taken on record by the Board of Directors in their meeting held on February 04,2025.
- The Statutory Auditors have carried out Limited Review of the aforesaid results and have issued their "Unmodified Report" thereon.
- The above financial results are prepared in accordance with the Indian Accounting Standards( IND AS) as prescribed under Section 133 of the companies Act,2013 and are in compliance with presentation and disclosure requirements of Regulation 33 of the SEBI (Listing obligations and Disclosure Requirements) Regulations,2015 (as Amended).
- The Company is operating in one segment only hence no segment results have been disclosed.
- As at December 31, 2024 the Company does not have any Subsidiary/Associate/Joint venture company(ies).
- Figures of the previous period have been regrouped to confirm to the figures of the current period's classification wherever necessary.

Place: Mumbai  
Date: February 04,2025



*Jitendra Shah*  
Jitendra Shah  
Managing Director  
DIN : 09377846





Independent Auditor's Review Report on the Quarterly Unaudited standalone Financial Results of the company pursuant to the regulation 33 and 52 of the SEBI(Listing Obligation and Disclosure Requirements)Regulation,2015,as amended

**Review Report to  
The Board of Directors,  
KREBS BIOCHEMICALS & INDUSTRIES LIMITED**

- a) We have reviewed the accompanying statement of unaudited standalone financial results of **M/s. KREBS BIOCHEMICALS & INDUSTRIES LIMITED** ("the company") for the quarter ended **31<sup>st</sup> December, 2024** (the "Statement") attached herewith, being submitted by the company pursuant to the requirements of Regulation 33 and 52 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015, as amended(the "Listing Regulations")
- b) The statement, which is the responsibility of the Company's Management and approved by the Board of Directors ,has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, Interim financial reporting (Ind AS 34) specified under section 133 of the Companies Act 2013 as amended, read with relevant rules issued there under and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the statement based on our review.
- c) We conducted our review in accordance with the Standard on Review Engagement (SRE) 2410, *Review of Interim Financial Information performed by the independent Auditor of Entity* issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.
- d) Based on our review conducted as above nothing has come to our attention that causes us to believe that the accompanying statement prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standards ('IND AS') specified under section 133 of the Companies Act 2013 read with relevant rules issued thereafter and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of listing regulations, including the manner in which it is to be disclosed, or that it contains any material misstatement.

**For Bhavani &Co.**

Chartered Accountants

Firm Registration No: 012

**CA S Kavitha Padmini**

Partner

Membership no: 229966

UDIN: 25229966BMJKPY3921



Place : Mumbai

Date : 04-02-2025



B. Statement on deviation or variation for proceeds of public issue, rights issue, preferential issue, qualified institutions placement etc: Not applicable

C. Format for disclosing outstanding default on loans and debt securities : Not applicable

D. Format for disclosure of related party transactions : Not applicable

E. Statement on impact of audit qualifications (for audit report with modified opinion) submitted alongwith annual audited financial results (standalone and consolidated separately) : Not Applicable

